- Home
- ATNM vs VRCA Comparison
ATNM vs VRCA Comparison
Compare ATNM & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- VRCA
- Stock Information
- Founded
- ATNM 2000
- VRCA 2013
- Country
- ATNM United States
- VRCA United States
- Employees
- ATNM N/A
- VRCA N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- VRCA Health Care
- Exchange
- ATNM Nasdaq
- VRCA Nasdaq
- Market Cap
- ATNM 51.5M
- VRCA 43.0M
- IPO Year
- ATNM N/A
- VRCA 2018
- Fundamental
- Price
- ATNM $1.54
- VRCA $0.49
- Analyst Decision
- ATNM Strong Buy
- VRCA Hold
- Analyst Count
- ATNM 3
- VRCA 5
- Target Price
- ATNM $4.67
- VRCA $6.00
- AVG Volume (30 Days)
- ATNM 229.8K
- VRCA 263.8K
- Earning Date
- ATNM 05-09-2025
- VRCA 05-13-2025
- Dividend Yield
- ATNM N/A
- VRCA N/A
- EPS Growth
- ATNM N/A
- VRCA N/A
- EPS
- ATNM N/A
- VRCA N/A
- Revenue
- ATNM N/A
- VRCA $7,179,000.00
- Revenue This Year
- ATNM N/A
- VRCA $127.85
- Revenue Next Year
- ATNM N/A
- VRCA $105.09
- P/E Ratio
- ATNM N/A
- VRCA N/A
- Revenue Growth
- ATNM N/A
- VRCA N/A
- 52 Week Low
- ATNM $1.03
- VRCA $0.38
- 52 Week High
- ATNM $8.64
- VRCA $9.36
- Technical
- Relative Strength Index (RSI)
- ATNM 49.81
- VRCA 42.86
- Support Level
- ATNM $1.56
- VRCA $0.49
- Resistance Level
- ATNM $1.69
- VRCA $0.73
- Average True Range (ATR)
- ATNM 0.11
- VRCA 0.07
- MACD
- ATNM -0.01
- VRCA -0.01
- Stochastic Oscillator
- ATNM 32.18
- VRCA 21.79
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.